The present invention relates to 5-chloro-2-difluoromethoxyphenylpyrazolopyrimidine compounds that are JAK inhibitors, in particular the compounds of formula (00A) and methods of use as Janus kinase inhibitors are described herein. The claimed use is in the treatment of inflammation and asthma.